Balasa Dinverno & Foltz’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.64M | Buy |
30,631
+2,141
| +8% | +$191K | 0.17% | 61 |
|
|
2022
Q2 | $2.6M | Buy |
28,490
+4,579
| +19% | +$406K | 0.16% | 61 |
|
|
2022
Q1 | $1.96M | Sell |
23,911
-2,142
| -8% | -$169K | 0.13% | 70 |
|
|
2021
Q4 | $2M | Sell |
26,053
-6,946
| -21% | -$553K | 0.13% | 76 |
|
|
2021
Q3 | $2.48M | Buy |
32,999
+853
| +3% | +$64.9K | 0.17% | 59 |
|
|
2021
Q2 | $2.5M | Buy |
32,146
+1,779
| +6% | +$132K | 0.18% | 55 |
|
|
2021
Q1 | $2.23M | Sell |
30,367
-7,913
| -21% | -$584K | 0.18% | 56 |
|
|
2020
Q4 | $2.99M | Buy |
38,280
+11,018
| +40% | +$843K | 0.25% | 38 |
|
|
2020
Q3 | $2.16M | Buy |
27,262
+4,228
| +18% | +$331K | 0.2% | 45 |
|
|
2020
Q2 | $1.7M | Sell |
23,034
-2,280
| -9% | -$172K | 0.19% | 51 |
|
|
2020
Q1 | $1.86M | Sell |
25,314
-17,049
| -40% | -$1.34M | 0.23% | 44 |
|
|
2019
Q4 | $3.68M | Sell |
42,363
-2,757
| -6% | -$226K | 0.39% | 25 |
|
|
2019
Q3 | $3.62M | Buy |
45,120
+10,294
| +30% | +$825K | 0.42% | 21 |
|
|
2019
Q2 | $2.79M | Buy |
34,826
+12,864
| +59% | +$985K | 0.32% | 29 |
|
|
2019
Q1 | $1.74M | Buy |
21,962
+3,304
| +18% | +$247K | 0.21% | 41 |
|
|
2018
Q4 | $1.36M | Buy |
18,658
+3,443
| +23% | +$243K | 0.17% | 50 |
|
|
2018
Q3 | $1.03M | Buy |
15,215
+1,298
| +9% | +$82.7K | 0.12% | 75 |
|
|
2018
Q2 | $806K | Buy |
13,917
+1,247
| +10% | +$70.4K | 0.12% | 78 |
|
|
2018
Q1 | $659K | Sell |
12,670
-240
| -2% | -$13K | 0.1% | 95 |
|
|
2017
Q4 | $693K | Sell |
12,910
-2,377
| -16% | -$132K | 0.1% | 87 |
|
|
2017
Q3 | $934K | Buy |
15,287
+627
| +4% | +$38K | 0.15% | 63 |
|
|
2017
Q2 | $897K | Buy |
14,660
+250
| +2% | +$15.2K | 0.15% | 68 |
|
|
2017
Q1 | $874K | Buy |
14,410
+258
| +2% | +$15.7K | 0.15% | 61 |
|
|
2016
Q4 | $795K | Buy |
14,152
+2,107
| +17% | +$123K | 0.14% | 66 |
|
|
2016
Q3 | $717K | Buy |
12,045
+394
| +3% | +$23K | 0.13% | 67 |
|
|
2016
Q2 | $640K | Sell |
11,651
-822
| -7% | -$43.7K | 0.11% | 72 |
|
|
2016
Q1 | $630K | Sell |
12,473
-732
| -6% | -$35.9K | 0.11% | 69 |
|
|
2015
Q4 | $666K | Sell |
13,205
-1,657
| -11% | -$83.5K | 0.11% | 69 |
|
|
2015
Q3 | $700K | Buy |
14,862
+750
| +5% | +$39.8K | 0.12% | 67 |
|
|
2015
Q2 | $767K | Sell |
14,112
-1,910
| -12% | -$107K | 0.12% | 53 |
|
|
2015
Q1 | $879K | Sell |
16,022
-1,132
| -7% | -$64.1K | 0.13% | 50 |
|
|
2014
Q4 | $930K | Sell |
17,154
-234
| -1% | -$13K | 0.13% | 45 |
|
|
2014
Q3 | $984K | Buy |
17,388
+1,139
| +7% | +$64K | 0.15% | 42 |
|
|
2014
Q2 | $897K | Buy |
16,249
+628
| +4% | +$34.3K | 0.1% | 39 |
|
|
2014
Q1 | $846K | Buy |
15,621
+165
| +1% | +$8.54K | 0.1% | 39 |
|
|
2013
Q4 | $738K | Buy |
15,456
+10
| +0.1% | +$457 | 0.1% | 39 |
|
|
2013
Q3 | $702K | Buy |
15,446
+200
| +1% | +$9.13K | 0.12% | 38 |
|
|
2013
Q2 | $676K | Buy |
+15,246
| New | +$681K | 0.12% | 40 |
|
Other funds holding MRK
Balasa Dinverno & Foltz's MRK Position: Q3 2022 in Review
Balasa Dinverno & Foltz increased its Merck (MRK) stake by 7.5% in Q3 2022, buying an estimated $191K and bringing the position to 30,631 shares worth $2.64M. The position accounts for 0.17% of the portfolio, ranked #61.
Balasa Dinverno & Foltz first reported a position in MRK in Q2 2013 and has held it in 38 quarters since. The position peaked at $3.68M in Q4 2019. 2,989 funds tracked by Wall St. Rank hold MRK as of Q3 2022.
- Balasa Dinverno & Foltz held 30,631 shares of Merck worth $2.64M as of Q3 2022.
- Balasa Dinverno & Foltz bought 2,141 Merck shares in Q3 2022, an estimated $191K.
- Merck made up 0.17% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #61 holding.
- Balasa Dinverno & Foltz first reported a position in Merck in Q2 2013 and has held it in 38 quarters since.
- Balasa Dinverno & Foltz's Merck position peaked at $3.68M in Q4 2019.
- 2,989 funds tracked by Wall St. Rank held Merck as of Q3 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.